Gonadal Steroids

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Seventh Edition

Volumn , Issue , 2009, Pages 117-123

  Venken, Katrien ^a   Boonen, Steven ^a   Bouillon, Roger ^a   Vanderschueren, Dirk ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Androgen receptor; Androgens; Endosteum; Estrogen receptor ; Estrogen receptor ; Estrogens; Genomic sex steroid action; Nongenomic sex steroid action; Osteoporosis; Periosteum; Progesterone; Progesterone receptor; Sex steroid receptors; Trabecular bone

Indexed keywords

EID: 84889495729     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470623992.ch24     Document Type: Chapter

References (84)

1. Albright F, Reifenstein EC 1948 Metabolie bone disease: Osteo-porosis. In: Albright F, Reifenstein EC (eds.) The Parathyroid Glands and Metabolie Bone Disease. Williams and Wilkins, Bal-timore, MD, USA, pp. 145-204.
2. Riggs BL, Khosla S, Melton LJ III 2002 Sex Steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279-302.
3. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C 2004 Androgens and bone. Endocr Rev 25:389-425.
4. Prior JC 1990 Progesterone as a bone-trophic hormone. Endocr Rev 11:386-398.
5. Vermeulen A, Verdonk L 1968 Studies on the binding of testos-terone to human plasma. Steroids 11:609-635.
6. Giorgi EP, Stein WD 1981 The transport of steroids into animal cells in culture. Endocrinology 108:688-697.
7. Wilson JD 2001 The role of 5alpha-reduction in steroid hormone physiology. Reprod Fertil Dev 13:673-678.
8. Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C, Jones M 2002 Aromatase-a brief overview. Annu Rev Physiol 64:93-127.
9. Longcope C 1998 Metabolism of estrogens and progestins. In: Frä-ser IS Jr, Lobo RA, Whitehead MI (eds.) Estrogens and Proges-tens in Clinical Practice. Churchill Livingstone. New York, NY, USA, pp. 89-94.
10. Griffin HG, Wilson JD 1994 Disorders of the testes and male reproductive tract. In: Wilson JD, Foster DW (eds.) Textbook of Endocrinology. Saunders, Philadelphia, PA, USA, pp. 799-852.
11. Kaufman JM, Vermeulen A 2005 The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26:833-876.
12. Khosla S, Melton LJ, Atkinson EJ, O-Fallon WM, Klee GG, Riggs BL 1998 Relationship of serum sex steroid levels and bone turn-over markers with bone mineral density in men: A key role for bio-available estrogen. J Clin Endocrinol Metab 83:2266-2275.
13. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The nuclear receptor superfamily: The second decade. Cell 83:835-839.
14. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Anders-son G, Enmark E, Pettersson K, Warner M, Gustafsson JA 2001 Mechanisms of estrogen action. Physiol Rev 81:1535-1565.
15. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM. French FS 1995 Androgen receptor defects: Historical, clini-cal, and molecular perspectives. Endocr Rev 16:271-321.
16. Savouret JF, Chauchereau A, Misrahi M, Lescop P, Mantel A, Bailly A, Milgrom E 1994 The progesterone receptor. Biological effects of progestins and antiprogestins. Hum Reprod 9(Suppl 1):7-U.
17. Tsai MJ, O'Malley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Bio-chem 63:451-486.
18. McKenna NJ, Lanz RB, O'Malley BW 1999 Nuclear receptor co-regulators: Cellular and molecular biology. Endocr Rev 20:321-344.
19. Shang Y, Myers M, Brown M 2002 Formation of the androgen receptor transcription complex. Mol Cell 9:601-610.
20. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P 2000 Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74:311-317.
21. Whitmarsh AJ, Davis RJ 1996 Transcription factor AP-1 regula-tion by mitogen-activated protein kinase signal transduction path-ways. J Mol Med 74:589-607.
22. Wiren KM, Toombs AR, Zhang XW 2004 Androgen inhibition of MAP kinase pathway and Elk-1 activation in proliferating osteo-blasts. J Mol Endocrinol 32:209-226.
23. Safe S 2001 Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Spl interactions. Vitam Horm 62:231-252.
24. Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M 2000 Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacol Rev 52:513-556.
25. Lösel RM, Falkenstein E, Feuring M, Schultz A, Tillmann HC, Rossol-Haseroth K, Wehling M 2003 Nongenomic steroid action: Controversies, questions, and answers. Physiol Rev 83:965-1016.
26. Pietras RJ, Szego CM 1977 Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 265:69-72.
27. Konoplya EF, Popoff EH 1992 Identification of the classical an-drogen receptor in male rat liver and prostate cell plasma mem-branes. Int J Biochem 24:1979-1983.
28. Wasserman WJ, Pinto LH, O'Connor CM, Smith LD 1980 Pro-gesterone induces a rapid increase in [Ca2+]in of Xenopus laevis oocytes. Proc Natl Acad Sei USA 77:1534-1536.
29. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ 2002 Linkage of rapid estrogen action to MAPK acti-vation by ERalpha-Shc association and She pathway activation. Mol Endocrinol 16:116-127.
30. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbon-danza C, Auricchio F 2000 Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 19:5406-5417.
31. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenel-lenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC 2001 Nongenotropic, sex-nonspecific signaling through the es-trogen or androgen receptors: Dissociation from transcriptional activity. Cell 104:719-730.
32. Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI. Bellido T. Manolagas SC 2003 Kinase-mediated regulation of common tran-scription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 111:1651-1664.
33. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA. Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Mano-lagas SC 2002 Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298:843-846.
34. Moverare S, Dahllund J, Andersson N, Islander U, Carlsten F, Gustafsson JA, Nilsson S, Ohlsson C 2003 Estren is a selective estrogen receptor modulator with transcriptional activity. Mol Pharmacol 64:1428-1433.
35. Windahl SH, Galien R, Chiusaroli R, Clement-Lacroix P, Morvan F, Lepescheux L, Nique F, Hörne WC, Resche-Rigon M, Baron R 2006 Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor. J Clin Invest 116:2500-2509.
36. Centrella M, McCarthy TL, Chang WZ, Labaree DC. Hochberg RB 2004 Estren (4-estren-3alpha,17beta-diol) is a prohormone that regulates both androgenic and estrogenic transcriptional ef-fects through the androgen receptor. Mol Endocrinol 18:1120-1130.
37. Krishnan V, Bullock HA, Yaden BC, Liu M, Barr RJ, Montrose-Rafizadeh C, Chen K, Dodge JA, Bryant HU 2005 The nongeno-tropic synthetic ligand 4-estren-3alphal7beta-diol is a high-affinity genotropic androgen receptor agonist. Mol Pharmacol 67:744-748.
38. Moverare S, Venken K, Eriksson AL, Andersson N, Skrtic S, Wergedal J, Mohan S, Salmon P, Bouillon R, Gustafsson JA, Vanderschueren D, Ohlsson C 2003 Differential effects on bone of estrogen receptor alpha and androgen receptor activation in or-chidectomized adult male mice. Proc Natl Acad Sei USA 100:13573-13578.
39. Seeman E 1997 From density to structure: Growing up and grow-ing old on the surfaces of bone. J Bone Miner Res 12:509-521.
40. Seeman E 2001 Clinical review 137: Sexual dimorphism in skeletal size, density, and strength. J Clin Endocrinol Metab 86:4576-4584.
41. Turner RT, Wakley GK, Hannon KS 1990 Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J Orthop Res 8:612-617.
42. Vandenput L, Swinnen JV, Boonen S, Van Herck E, Erben RG. Bouillon R, Vanderschueren D 2004 Role of the androgen recep-tor in skeletal homeostasis: The androgen-resistant testicular femi-nized male mouse model. J Bone Miner Res 19:1462-1470.
43. Kawano H, Sato T, Yamada T, Matsumoto T, Sekine K, Watanabe T, Nakamura T, Fukuda T, Yoshimura K, Yoshizawa T, Aihara K, Yamamoto Y, Nakamichi Y, Metzger D, Chambon P, Nakamura K, Kawaguchi H, Kato S 2003 Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sei USA 100:9416-9421.
44. Venken K, De Gendt K, Boonen S, Ophoff J, Bouillon R, Swinnen JV, Verhoeven G, Vanderschueren D 2006 Relative impact of androgen and estrogen receptor activation in the effects of andro-gens on trabecular and cortical bone in growing male mice: A study in the androgen receptor knock-out mouse model. J Bone Miner Res 21:576-585.
45. Lea C, Kendall N, Flanagan AM 1996 Casodex (a nonsteroidal antiandrogen) reduces cancellous, endosteal, and periosteal bone formation in estrogen-replete female rats. Calcif Tissue Int 58:268-272.
46. Dagogo-Jack S, al-Ali N, Qurttom M 1997 Augmentation of bone mineral density in hirsute women. J Clin Endocrinol Metab 82:2821-2825.
47. Windahl SH. Vidal O, Andersson G, Gustafsson JA, Ohlsson C 1999 Increased cortical bone mineral content but unchanged tra-becular bone mineral density in female ERbeta(-/-) mice. J Clin Invest 104:895-901.
48. Windahl SH, Hollberg K. Vidal O, Gustafsson JA, Ohlsson C, Andersson G 2001 Female estrogen receptor beta-/-mice are partially protected against age-related trabecular bone loss. J Bone Miner Res 16:1388-1398.
49. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B. Williams TC, Lubahn DB, Korach KS 1994 Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056-1061.
50. Gennari L, Nuti R, Bilezikian JP 2004 Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab 89:5898-5907.
51. Bouillon R, Bex M, Vanderschueren D, Boonen S 2004 Estrogens are essential for male pubertal periosteal bone expansion. J Clin Endocrinol Metab 89:6025-6029.
52. Bass S, Delmas PD, Pearce G, Hendrich E, Tabensky A, Seeman E 1999 The differing tempo of growth in bone size, mass, and density in girls is region-specific. J Clin Invest 104:795-804.
53. Jarvinen TL, Kannus P, Sievanen H 2003 Estrogen and bone-a reproductive and locomotive perspective. J Bone Miner Res 18:1921-1931.
54. Vanderschueren D, Venken K, Bouillon R 2004 Animal models for gender-based skeletal differences. In: Legato M (ed.) Prin-ciples of Gender-Specific Medicine. Elsevier Academic Press, San Diego, CA, USA, pp. 1043-1051.
55. Juul A 2001 The effects of oestrogens on linear bone growth. Hum Reprod Update 7:303-313.
56. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E 1997 Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82:2386-2390.
57. Manolagas SC 2000 Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-137.
58. Riggs BL 2000 The mechanisms of estrogen regulation of bone resorption. J Clin Invest 106:1203-1204.
59. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF 1996 Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-(3. Nat Med 2:1132-1136.
60. Michael H, Harkonen PL, Vaananen HK, Hentunen TA 2005 Estrogen and testosterone use different cellular pathways to in-hibit osteoclastogenesis and bone resorption. J Bone Miner Res 20:2224-2232.
61. Nakamura T. Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Tak-eda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ. Chambon P, Kato S 2007 Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130:811-823.
62. Chen Q, Kaji H, Kanatani M. Sugimoto T, Chihara K 2004 Tes-tosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. Horm Metab Res 36:674-678.
63. Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dal-rymple SA, Murray R, Manolagas SC 1995 Regulation of inter-leukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 95:2886-2895.
64. Huber DM, Bendixen AC, Pathrose P, Srivastava S, Dienger KM, Shevde NK, Pike JW 2001 Androgens suppress osteoclast forma-tion induced by RANKL and macrophage-colony stimulating fac-tor. Endocrinology 142:3800-3808.
65. Riggs BL, Parfitt AM 2005 Drugs used to treat osteoporosis: The critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20:177-184.
66. Seeman E 2002 Pathogenesis of bone fragility in women and men. Lancet 359:1841-1850.
67. Seeman E 2003 Periosteal bone formation-a neglected determi-nant of bone strength. N Engl J Med 349:320-323.
68. Vandenput L, Boonen S, Van Herck E, Swinnen JV, Bouillon R, Vanderschueren D 2002 Evidence from the aged orchidectomized male rat model that 17beta-estradiol is a more effective bone-sparing and anabolic agent than 5alpha-dihydrotestosterone. J Bone Miner Res 17:2080-2086.
69. Venken K, Boonen S, Van Herck E, Vandenput L, Kumar N, Sitruk-Ware R, Sundaram K, Bouillon R, Vanderschueren D 2005 Bone and muscle protective potential of the prostate-sparing syn-thetic androgen 7alpha-methyl-19-nortestosterone: Evidence from the aged orchidectomized male rat model. Bone 36:663-670.
70. Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, John-ston CC 1997 Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 100:1755-1759.
71. Greendale G, Edelstein S, Barrett-Connor E 1997 Endogenous sex steroids and bone mineral density in older women and men. The Rancho Bernardo Study. J Bone Miner Res 12:1833-1841.
72. Van Pottelbergh I, Goemaere S, Kaufman JM 2003 Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab 88:3075-3081.
73. Riggs BL, Khosla S, Melton LJ III 1998 A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contrib-utes to bone loss in aging men. J Bone Miner Res 13:763-773.
74. Eastell R 2007 Aromatase inhibitors and bone. J Steroid Biochem Mol Biol 106:157-161.
75. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF. Haddad JG Jr, Strom BL 1999 Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966-1972.
76. Kenny AM, Prestwood KM, Marcello KM, Raisz LG 2000 Deter-minants of bone density in healthy older men with low testoster-one levels. J Gerontol A Biol Sci Med Sci 55A:M492-M497.
77. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooper-berg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Prin-cipal results From the Women's Health Initiative randomized con-trolled trial. JAMA 288:321-333.
78. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Pren-tice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefan-ick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wasser-theil-Smoller S 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712.
79. Smith CL, O'Malley BW 2004 Coregulator function: A key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45-71.
80. Anonymous 1998 Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collabo-rative Group. Lancet 351:1451-1467.
81. Johnell O, Kanis JA, Black DM, Balogh A, Poor G, Sarkar S, Zhou C, Pavo I 2004 Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res 19:764-772.
82. Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD 2006 Anti-vertebral fracture efficacy of raloxifene: A meta-analysis. Os-teoporos Int 17:313-316.
83. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669.
84. Chen J, Kim J, Dalton JT 2005 Discovery and therapeutic promise of selective androgen receptor modulators. Mol Interv 5:173-188.